Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
On May 9, 2018, Rennova Health, Inc. (the “Company”) held a Special Meeting of Stockholders to (1) approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares, (2) approve the Company’s new 2018 Incentive Award Plan, and (3) authorize an adjournment of the Special Meeting, if necessary, if a quorum is present to solicit additional proxies if there are not sufficient votes in favor of the above proposals.
Proposal 1 was approved by the Company’s stockholders. Set forth below are the final voting results for the proposal submitted to the stockholders at the Special Meeting.
Proposal 1: To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 500,000,000 to 3,000,000,000 shares.
| For: | 258,502,802 shares |
| Against: | 210,955,950 shares |
| Abstain: | 1,534,353 shares |
Proposal 2 was defeated by the Company’s stockholders. Set forth below are the final results for the proposal submitted to the stockholders at the Special Meeting.
Proposal 2: To approve the Company’s new 2018 Incentive Award Plan.
| For: | 130,570,303 shares |
| Against: | 83,478,005 shares |
| Abstain: | 59,760,533 shares |
| Broker Non-Votes: | 197,184,264 shares |
Proposal 3, to authorize an adjournment of the Special Meeting, was not voted on. The Company had previously withdrawn its proposal to authorize a reverse stock split, so that proposal was also not voted on at the Special Meeting. No other business was conducted at the Special Meeting. The Company’s common stock and Series F Preferred Stock voted on the proposals together as a single class and all vote totals above are an aggregate of the votes of the shares of the common stock and Series F Preferred Stock.
For more information regarding the proposals considered at the Special Meeting, see the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 14, 2018.
About Rennova Health, Inc. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
